<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>Drugmaker's Shares Triple on Leukemia Vaccine News — Live Feed</title><link>https://www.live-feeds.com/feed/drugmaker-s-shares-triple-on-leukemia-vaccine-news</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/drugmaker-s-shares-triple-on-leukemia-vaccine-news/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Drugmaker's Shares Triple on Leukemia Vaccine News</title><link>https://www.live-feeds.com/feed/drugmaker-s-shares-triple-on-leukemia-vaccine-news</link><guid isPermaLink="false">https://www.live-feeds.com/feed/drugmaker-s-shares-triple-on-leukemia-vaccine-news#u213361</guid><pubDate>Sun, 22 Nov 2026 11:52:07 +0000</pubDate><description>Sellas Life Sciences shares tripled following positive clinical trial results for an experimental blood cancer immunotherapy. The leukemia vaccine successfully passed a key trial, improving survival rates and reducing the risk of death in patients with acute myeloid leukemia. This development adds to a breakthrough year for cancer drugs and places the treatment among biotech industry highlights. Alongside the clinical milestone, the company announced the pricing of a one hundred fifty million dollar underwritten public offering.Why it mattersThe positive data for the acute myeloid leukemia vac</description></item>
</channel></rss>